Harvard Bioscience (HBIO) Short term Debt (2013 - 2025)

Harvard Bioscience (HBIO) has 13 years of Short term Debt data on file, last reported at $34.0 million in Q3 2025.

• On a quarterly basis, Short term Debt rose 841.96% year-over-year to $34.0 million in Q3 2025; TTM through Sep 2025 was $34.0 million, a 841.96% increase from a year earlier, with the FY2024 full-year figure at $37.0 million, up 530.76% from the prior year.
• Short term Debt for Q3 2025 stood at $34.0 million, down from $34.9 million in the prior quarter.
• Over the last five years, Short term Debt for HBIO reached as high as $37.0 million in Q4 2024 and fell as low as $2.0 million in Q1 2021.
• Historically, Short term Debt has averaged $10.0 million across 5 years, with a median of $3.5 million in 2023.
• Across the five-year window, Short term Debt declined 29.82% in 2021 and surged 866.61% in 2025, its largest moves.
• Year by year, Short term Debt stood at $3.2 million in 2021, then increased by 17.81% to $3.8 million in 2022, then surged by 53.74% to $5.9 million in 2023, then surged by 530.76% to $37.0 million in 2024, then dropped by 8.09% to $34.0 million in 2025.
• Per Business Quant data, the three most recent Short term Debt figures were $34.0 million in Q3 2025, $34.9 million in Q2 2025, and $36.0 million in Q1 2025.